The global community is well aware of the devastatinTop Generalizable Antivirals for Stockpiling in Emergencies: A Review and Gap Analysis

The global community is well aware of the devastating potential of viral outbreaks. From the ongoing challenges posed by seasonal flu to the devastation caused by the COVID-19 pandemic, the need for effective antiviral therapies is clear. While vaccines and public health measures can help to reduce some risks, antiviral drugs remain a powerful tool for treating viral infections once they occur (Andrei, 2021). Given the unpredictable nature of viral threats, it is critical to consider which antivirals are most generalizable to a wide range of viral pathogens and which treatment gaps still need to be filled (Groaz, 2021).

1. Remdesivir: Broad-Spectrum Activity Against RNA Viruses

Remdesivir (brand name Veklury), which was initially developed to treat Ebola, has emerged as an important antiviral agent in the fight against RNA viruses (Warren, 2016). It inhibits viral RNA-dependent RNA polymerase, an enzyme required for viral replication. Remdesivir is effective against several coronaviruses, including SARS-CoV-2, and was approved for emergency use during the COVID-19 pandemic (Beigel, 2020).

Remdesivir has been tested and approved for COVID-19, but it has also shown promise against a variety of other RNA viruses. Its effectiveness against other viral infections, such as Zika, hepatitis C, and even certain strains of influenza, is being studied (Radoshitzky, 2023).

Remdesivir's limitations in treating certain viral infections, such as its relatively narrow efficacy window and intravenous administration requirement, make it difficult to use in an emergency (Piscoya, 2020). This limitation highlights the need for further optimization in terms of oral bioavailability and broad antiviral activity across multiple viral families.

2. Favipiravir: Effective Against Multiple RNA Viruses

Favipiravir (Avigan), an antiviral medication originally developed for influenza, has been shown to be effective against a variety of RNA viruses, including Ebola, Zika, and SARS-CoV-2 (Marlin, 2022). Favipiravir inhibits viral RNA polymerase, which prevents virus replication (Shiraki, 2020). It is particularly appealing for stockpiling due to its demonstrated efficacy in treating viral infections such as influenza and its ability to be repurposed for novel viruses.

The drug has been used successfully in a variety of emergency situations, including in Japan during the COVID-19 outbreak, but its effectiveness is still debated (Cao, 2020). While it shows promise in reducing the severity and duration of illness in influenza patients, further clinical trials are needed to fully establish its role against other viral pathogens (Shiraki, 2020).

Favipiravir is typically administered orally, which makes it more suitable for stockpiling compared to intravenous alternatives (Bielicki, 2020). However, the drug's side effects, such as teratogenicity (causing birth defects), and its limited efficacy in some viral infections, suggest that additional antiviral therapies will still be required to fill in the gaps (Sangawa, 2013).

3. Molnupiravir: An Oral Option for RNA Viruses

Molnupiravir, like remdesivir and favipiravir, targets the RNA-dependent RNA polymerase enzyme, causing viral mutations that inhibit replication (FDA, 2021). Molnupiravir is particularly appealing due to its oral administration, which makes it far easier to stockpile and distribute than intravenous treatments (ASHP, 2023).

Molnupiravir has been shown to reduce the severity of COVID-19 and shorten recovery time, especially in patients who have mild to moderate symptoms (Sun, 2023). Its broad activity against other RNA viruses, such as influenza and RSV (respiratory syncytial virus), suggests that it could be a useful tool for managing future viral outbreaks (Painter, 2021). As an oral medication, it has significant advantages in emergency preparedness because it can be stored and distributed to affected populations more easily.

However, Molnupiravir is not widely accepted as a first-line antiviral treatment (Jayk, 2022). Its limitations include a lack of strong efficacy data for specific populations (e.g., high-risk individuals or those with severe disease), concerns about mutagenicity (the possibility of causing mutations), and ongoing debates about its long-term safety.

4. Acyclovir: A Standby for Herpesviruses

Acyclovir (Zovirax) is an antiviral medication commonly used to treat herpes simplex virus (HSV) infections, varicella-zoster virus (VZV), and other herpesviruses (Piret, 2011). It works by inhibiting viral DNA polymerase, which prevents viral DNA replication. Despite being specific to herpesviruses, acyclovir remains an essential component of any antiviral arsenal due to the ongoing threat posed by herpes simplex infections, particularly in immunocompromised individuals (Whitley, 2006).

The drug is widely used and well tolerated, and it is available in oral, intravenous, and topical formulations, making it useful in a variety of emergency situations. Acyclovir's track record and widespread use for herpesvirus infections make it essential for viral emergencies, especially in populations at risk of herpesvirus reactivation, such as organ transplant recipients and HIV/AIDS patients (Piret, 2011).

While acyclovir is effective against herpesvirus infections, it is ineffective against non-herpesvirus infections, highlighting the need for additional antiviral drugs that can treat a wider range of pathogens.

5. Interferons: Enhancing Host Immune Response

Interferons (IFNs) are proteins that help the immune system respond to viral infections. Alpha, beta, and gamma interferons have been used to treat a wide range of viral diseases, including hepatitis B and C, and, more recently, COVID-19. Interferon therapy improves the innate immune system's ability to detect and eradicate viral infections (Monk, 2021).

Interferons are considered generalizable antivirals, which can be used to treat a wide range of viral infections (Samuel, 2001). They are particularly effective in treating chronic viral infections and can be used in combination with other antiviral medications. However, interferons are associated with significant side effects, such as flu-like symptoms and immunosuppression, which limit their use in some patients.

These side effects may limit their utility in pandemic situations, but their role in treating persistent or difficult-to-treat infections warrants additional research into how to optimize their use.

Gaps in the Current Antiviral Stockpile

While the antivirals listed above provide broad coverage against several key viral pathogens, significant gaps exist in the ability to effectively treat all viral outbreaks. The key gaps are as follows:

1. Lack of Universal Coverage: Currently, no antiviral drug provides complete protection against all viral families, including RNA, DNA, and retroviruses. Emerging viruses, particularly those with high mutation rates, such as HIV or influenza, can develop resistance to current therapies.

2. Antiviral Resistance: Overuse and misuse of antivirals, can lead to resistance, decreasing their effectiveness over time. More research is needed to better understand the dynamics of antiviral resistance and develop drugs with stronger, longer-lasting efficacy.

3. Access and Distribution: Many effective antivirals, particularly those administered intravenously, such as Remdesivir, are difficult to scale for global distribution in emergency situations. Oral antivirals, such as Molnupiravir, provide a more feasible solution, but their use requires careful monitoring and additional research into broader applications.

4. Safety Concerns: Many broad-spectrum antivirals, including favipiravir and molnupiravir, raise safety concerns, such as teratogenicity or long-term mutagenic effects, that must be addressed before they can be used safely in an emergency.

Conclusion

Stockpiling a diverse set of generalizable antivirals is critical for global pandemic readiness. Remdesivir, favipiravir, and molnupiravir are promising treatments for future viral outbreaks due to their broad-spectrum activity. However, gaps in universal viral coverage, antiviral resistance, and drug safety remain significant obstacles. The next stage of antiviral development should concentrate on increasing drug efficacy across a broader range of viral families, improving safety profiles, and overcoming logistical barriers to rapid distribution. Robust stockpiles, combined with strategic research into next-generation antivirals, will be critical in mitigating the impact of future viral pandemics.

References

ASHP. (2023, February 23). Molnupiravir monograph for professionals. Drugs.com. https://www.drugs.com/monograph/molnupiravir.html#dosage 

Andrei, G. (2021). Vaccines and antivirals: Grand challenges and great opportunities. Frontiers in Virology, 1. https://doi.org/10.3389/fviro.2021.666548

Beigel, J. H., Tomashek, K. M., Dodd, L. E., Mehta, A. K., Zingman, B. S., Kalil, A. C., … Lane, H. C. (2020). Remdesivir for the treatment of Covid-19—Final report. The New England Journal of Medicine, 383(19), 1813–1826. https://doi.org/10.1056/NEJMoa2007764

Bielicki, J. A., et al. (2020). "The Role of Oral Favipiravir in the Treatment of COVID-19." Clinical Infectious Diseases, 71(12), e753–e755. https://doi.org/10.1093/cid/ciaa787

Cao, Y., Li, L., Feng, Z., et al. (2020). "Efficacy and safety of Favipiravir for the treatment of COVID-19." The Lancet Infectious Diseases, 20(7), 809-810. https://doi.org/10.1016/S1473-3099(20)30281-6

FDA. (2021, December 23). Coronavirus (COVID-19) update: FDA authorizes additional oral antiviral for treatment of covid-19 in certain adults. U.S. Food and Drug Administration. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-oral-antiviral-treatment-covid-19-certain?utm_source=chatgpt.com 

Groaz, E., De Clercq, E., & Herdewijn, P. (2021). Anno 2021: Which antivirals for the coming decade? Annual Reports in Medicinal Chemistry, 57, 49–107. https://doi.org/10.1016/bs.armc.2021.09.004

Jayk Bernal, A., Gomes da Silva, M. M., Musungaie, D. B., Kovalchuk, E., Gonzalez, A., Delos Reyes, V., … & Owen, R. (2022). Molnupiravir for oral treatment of COVID?19 in nonhospitalized patients. New England Journal of Medicine, 386(6), 509–520. https://doi.org/10.1056/NEJMoa2116044

Marlin, R., Desjardins, D., Contreras, V. et al. Antiviral efficacy of favipiravir against Zika and SARS-CoV-2 viruses in non-human primates. Nat Commun 13, 5108 (2022). https://doi.org/10.1038/s41467-022-32565-w

Monk, P. D., Marsden, R. J., Tear, V. J., Brookes, J., Batten, T. N., Mankowski, M., … & Cornall, R. J. (2021). Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS?CoV?2 infection: a randomised, double?blind, placebo?controlled, phase 2 trial. The Lancet Respiratory Medicine, 9(2), 196–206. https://doi.org/10.1016/S2213-2600(20)30511-7

Painter WP, Holman W, Bush JA, Almazedi F, Malik H, Eraut NCJE, Morin MJ, Szewczyk LJ, Painter GR.(2021).Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity against SARS-CoV-2. Antimicrob Agents Chemother65:10.1128/aac.02428-20.https://doi.org/10.1128/aac.02428-20

Piret, J., & Boivin, G. (2011). Resistance of herpes simplex viruses to nucleoside analogues: Mechanisms, prevalence, and management. Antimicrobial Agents and Chemotherapy, 55(2), 459–472. https://doi.org/10.1128/AAC.00796-10

Piscoya, A., Ng-Sueng, L. F., Parra del Riego, A., Cerna-Viacava, R., Pasupuleti, V., et al. (2020). Efficacy and harms of remdesivir for the treatment of COVID-19: A systematic review and meta-analysis. PLOS ONE, 15(12), e0243705. https://doi.org/10.1371/journal.pone.0243705

Radoshitzky, S. R., Iversen, P., Lu, X., et al. (2023). Expanded profiling of remdesivir as a broad-spectrum antiviral and low potential for interaction with other medications in vitro. Scientific Reports, 13, 3131. https://doi.org/10.1038/s41598-023-29517-9

Samuel, C. E. (2001). Antiviral actions of interferons. Clinical Microbiology Reviews, 14(4), 778–809. https://doi.org/10.1128/CMR.14.4.778-809.2001

Sangawa, H., Komeno, T., Nishikawa, H., & Yoshida, A. (2013). "Mechanism of teratogenicity induced by the anti-influenza drug favipiravir in rodents." Journal of Toxicological Sciences, 38(6), 1007–1013. https://doi.org/10.2131/jts.38.1007

Shiraki, K., & Daikoku, T. (2020). Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. Pharmacology & Therapeutics, 209, 107512. https://doi.org/10.1016/j.pharmthera.2020.107512

Sun, M., Lai, H., Huang, J., Liu, J., Li, Y., Tian, J., Zhang, C., Estill, J., Zhang, Z., & Ge, L. (2023). Molnupiravir for the treatment of non-severe COVID-19: A systematic review and meta-analysis of 14 randomized trials with 34,570 patients. Journal of Antimicrobial Chemotherapy, 78 (9), 2131–2139. https://doi.org/10.1093/jac/dkad216

Warren, T. K., Jordan, R., Lo, M. K., et al. (2016). Therapeutic efficacy of GS-5734 against Ebola virus in rhesus monkeys. Nature, 531(7594), 381–385. https://doi.org/10.1038/nature17180

Whitley, R. J. (2006). Herpes simplex encephalitis: Adolescents and adults. Antiviral Research, 71(2–3), 141–148. https://doi.org/10.1016/j.antiviral.2006.08.007